Communication of the meeting of Transparency Council No. 12/2026 on 23 March 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 12/2026 on 23 March 2026 during which the following resolutions were adopted:

1. At its meeting on 23 March 2026, the Transparency Council adopted position No. 34/2026 on the evaluation of Embavi (apixaban) for the indication: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
2. At its meeting on 23 March 2026, the Transparency Council adopted position No. 35/2026 on the evaluation of the drug Apixaban Adamed (apixaban) for the indication: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation
3. At its meeting on 23 March 2026, the Transparency Council adopted position No. 36/2026 on the appropriateness of classifying the healthcare service “Fundus examination using a fundus camera with a screening assessment by a diabetologist or ophthalmologist or using artificial intelligence (AI) software”
4. At its meeting on 23 March 2026, the Transparency Council adopted position No. 37/2026 on the appropriateness of covering healthcare services related to human genome testing using next-generation sequencing (NGS)
5. At its meeting on 23 March 2026, the Transparency Council adopted opinion No. 38/2026 on “Genetic testing for familial hypercholesterolemia in children up to 18 years of age – NGS”
6. At its meeting on 23 March 2026, the Transparency Council adopted opinion No. 39/2026 on the inclusion of medicinal products containing the active ingredient pregabalin in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., neuropathy in children up to 18 years of age

Transparency Council meeting protocol >>